Supplementary Table 1. Optimal First-Line Immune Checkpoint Inhibitor Treatment in Lung Cancer: How to Choose?
收藏数据链接：
官方服务：
资源简介：
<i>ICI-Related Phase III RCTs in Previously Untreated Advanced NSCLC without Driver Mutations</i>
提供机构：
Taylor & Francis创建时间：
2022-05-03
